Abstract Library

#4393 Surufatinib plus trans arterial embolisation (TAE) vs. surufatinib monotherapy in neuroendocrine tumour with liver metastasis: Updated results from the prospective, randomised, controlled trial

Introduction: The liver is the main metastasis site for NETs. Surufatinib (SUR), an oral TKI, is standard therapy for advanced NETs. TAE is the primary local intervention for unresectable hepatic NETs.

Conference:

Presenting Author: Cao D

Authors: Cao D, Li X, You X, Li R, Xiang J,

Keywords: NET, Liver metastasis, Surufatinib, TAE,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#3956 Comparative efficacy of Surufatinib plus transarterial embolization versus Surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomised, controlled trial

Introduction: Surufatinib (SUR), an oral tyrosine kinase inhibitor, is a standard treatment for advanced NETs. Transarterial embolization (TAE) is a key local treatment for inoperable liver metastases from NETs.

Conference:

Presenting Author:

Authors: Li X, Li R, Cheng K, Cao D,

Keywords: Surufatinib, transarterial embolization, neuroendocrine tumor, liver metastasis,

#1868 Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS)

Introduction: The role of Primary Tumor resection in advanced metastatic NEN is discussed controversely.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Begum N

Authors: Begum N, Pavel M, Goretzki P, Vonthein R,

Keywords: Prospective Randomized, Controlled Trial, Surgery, Role of Primary Resection,